25975-59-1

Usage

Uses

Used in Pharmaceutical Industry:
5-ANDROSTENEDIOL is used as a pharmaceutical compound for its potential role in the treatment of prostate cancer. It functions as a C19-steroidal androgen receptor modulator, which has been studied for its effects on androgen receptors, potentially offering a new approach to managing prostate cancer.
Additionally, due to its anabolic steroid properties, 5-ANDROSTENEDIOL may also be used in the development of other therapeutic applications related to androgen receptor interactions, although further research is needed to explore these possibilities.

InChI:InChI=1/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2,12-17,19-20H,3-10H2,1H3/t12?,13-,14+,15+,16-,17?,18-/m0/s1

Upstream product

• 31321-37-6 3β,17β-diacetoxy-19-norandrost-5-ene 
• 734-32-7 estra-4-ene-3,17-dione 
• 42028-18-2 17β-hydroxyestr-5-en-3-one 
• 64-17-5 ethanol 
• 4999-76-2 3,17β-diacetoxyoestra-3,5-diene 
• 109-99-9 tetrahydrofuran 
• 434-22-0 19-nortestosterone 
• 70286-48-5 3-acetoxy-19-nor-androsta-3,5-dien-17-one 

Downstream Products

• 571-92-6 6-ketoestradiol 
• 50-28-2 estradiol 

Relevant academic research and scientific papers

OXIDATIVE β-FRAGMENTATION OF 19-NOR-5α-ANDROSTANE-3β,5,17β-TRIOL 3,17-DIACETATE

The preparation of 19-nor-5α-androstane-3β,5,17β-triol 3,17-diacetate (10) is described.When this alcohol was treated with the mercuric oxide-iodine reagent, it underwent fragmentation of the C(5)-C(10) bond with formation of a new type of 10-membered ring containing 5,10-seco-steroidal compounds, i.e. (Z)-and (E)-19-nor-3β,17β-diacetoxy-5,10-seco-androst-1(10)-en-5-one (11 and 12), in 27 and 49percent yield, respectively.

First synthesis of a steroid containing an unstable 19-nor-androsta-1,5-dien-3-one system

Mechanisms involved in the maintenance of human pregnancy and initiation of labour are poorly defined. A novel steroid hormone named estradienolone (ED), and having an unusual 19-nor-androsta-1,5-dien-3-one system, was previously reported. However, ED is scarcely available from urine, placenta and blood of pregnant women. For this reason, we have synthesized ED in order to verify its proposed structure. Although a 1,5-dien-3-one system had already been described for a C19-steroid (androstane) nucleus (no possible aromatization), the synthesis of the 19-nor-analogue is a major challenge because this system is very sensitive to aromatization. We now describe the successful construction and characterization of this unstable system. Starting from nortestosterone, the synthesis of 17β-hydroxy-19-nor-androsta-1,5-dien-3-one (1) is based on a protection of the 5,6-double bond, the introduction of the second 1,2-double bond, the careful recovery of the exo double bond and a final regioselective oxidation or reduction.

PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.